Published • loading... • Updated
Cancer patient becomes first to receive 'landmark' treatment
The early-stage trial is testing donor-derived immune cells that target MAGE-A4, and researchers say many participants have few other survival options.
- On Friday, Tracy Tomlinson, 58, became the first patient globally to receive ZI-MA4-1, an experimental engineered immune-cell therapy, at the Christie in Manchester as part of an early-phase clinical trial.
- Tomlinson, diagnosed with advanced ovarian cancer shortly before Christmas 2020, endured multiple recurrences despite surgery and chemotherapy. Last year, the Christie's early-phase clinical trials team screened her and identified her as a suitable candidate.
- Engineered Natural Killer cells with T-cell receptors target tumors producing the Mage-A4 protein. Dr. Jon Lim, consultant medical oncologist at the Christie, notes this living cell approach offers "a little bit more targeted" treatment than alternatives.
- While the study primarily assesses safety, Tomlinson admitted being the first person in the world to receive the treatment sparked doubt: "Am I doing the right thing?" because it felt "a little bit scary."
- Researchers designed ZI-MA4-1 as an off-the-shelf therapy, manufacturing hundreds of doses from a single batch to reduce costs and waiting times. The Christie and Royal Marsden in London are testing the therapy across ovarian, lung, sarcoma, and head-and-neck cancers.
Insights by Ground AI
17 Articles
17 Articles
British Woman Becomes First Patient to Receive Ready-Made Cancer Cell Therapy in World-First Trial
A British woman has become the first patient in the world to receive a pioneering 'ready-made' cancer cell therapy, marking a significant milestone in the development of next-generation cancer treatments. Tracy Tomlinson, 58, from Chadderton in Greater Manchester, received the experimental treatment at The Christie NHS Foundation Trust in Manchester as part of an international clinical trial evaluating a new type of engineered immune-cell therap…
·United Kingdom
Read Full Article
Coverage Details
Total News Sources17
Leaning Left4Leaning Right2Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 31%
C 54%
15%
Factuality
To view factuality data please Upgrade to Premium
